MEDIA AVAILABILITY
Scientists Report on Trial of Early-Generation Ebola, Marburg Vaccine Candidates
Scientists Report on Trial of Early-Generation Ebola, Marburg Vaccine Candidates
NIH-Sponsored Trial in Uganda Informed Development of Current NIAID/GSK Vaccine Candidate
Scientists Report on Trial of Early-Generation Ebola, Marburg Vaccine Candidates
NIH-Sponsored Trial in Uganda Informed Development of Current NIAID/GSK Vaccine Candidate
Results of an early-stage clinical trial of two experimental vaccines against Ebola and Marburg viruses—the first to be completed in an African country—showed that they were safe and induced immune responses in healthy Ugandan adult volunteers. Developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, the experimental vaccines (called DNA vaccines) were predecessors to a next-generation candidate vaccine, called the NIAID/GSK Ebola vaccine, which is currently in clinical development. The NIAID/GSK vaccine incorporates Ebola gene segments into a carrier derived from a chimpanzee adenovirus. It is being tested in several Phase 1 clinical trials around the world, with larger trials planned for early 2015.
.png)
No hay comentarios:
Publicar un comentario